Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of lenalidomide (Revlimid) in patients with MALT lymphoma
2009-010947-15Phase 2Completed
- Sponsor
- Medical University of Vienna, Department of Internal Medicine I, Division of Oncology
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by Medical University of Vienna, Department of Internal Medicine I, Division of Oncology. Primary endpoint: Clinical response. Started Apr 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2009-010947-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010947-15.